Pediatric Puzzler: Can it be IBD? Severe abdominal findings overwhelm a 12-year-old

Food Insecurity and the Dangers of Infant Formula Dilution

“While our study is small, its results are powerful and have implications not only for MIS-C, but potentially for long COVID,” said lead author Lael Yonker, MD.

January 30th 2023

Alopecia areata data: Upadacitinib demonstrates improvements in scalp hair coverage

Demystifying Infant Formula

Achieving the primary endpoint, 44.6% and 54.3% of patients treated with upadacitinib (15 mg and 30 mg) reached 80% or more scalp hair coverage.

October 11th 2022

The Leukemia & Lymphoma Society Unveils Name Change to Reach All Blood Cancer Patients

The Leukemia & Lymphoma Society

July 29th 2025

FDA approves pegcetacoplan as first treatment for C3 glomerulopathy or IC-MPGN

July 29th 2025

Larazotide safe, could improve MISC symptoms as adjuvant therapy

Pegcetacoplan (Empaveli; Apellis Pharmaceuticals) is indicated for patients 12 years or older to reduce proteinuria.

Related Content

Food Insecurity and the Dangers of Infant Formula Dilution

“While our study is small, its results are powerful and have implications not only for MIS-C, but potentially for long COVID,” said lead author Lael Yonker, MD.

January 30th 2023

Alopecia areata data: Upadacitinib demonstrates improvements in scalp hair coverage

Demystifying Infant Formula

Achieving the primary endpoint, 44.6% and 54.3% of patients treated with upadacitinib (15 mg and 30 mg) reached 80% or more scalp hair coverage.

October 11th 2022